RxDoctor Payments Data

Paul Johnson

Family · Hammond, LANPI 1336847706

Payments from drug & device makers

$162in general payments, 2019–2025

Across 10 payments — averaging $16.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$28
  • Boehringer Ingelheim$27
  • Lilly USA, LLC$19
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$18
  • GSK$18
  • Teva Pharmaceuticals USA, Inc.$16
  • plus $35 from 3 others

What the payments were for

  • Food & beverage$162100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$162 in reported general payments places this provider in the 25th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$37,723
Medicare patients
149
Services billed
595

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin154$108,931
EliquisApixaban126$107,649
MounjaroTirzepatide41$42,791
JanuviaSitagliptin Phosphate44$40,008
OzempicSemaglutide40$37,536
LinzessLinaclotide41$26,594
XareltoRivaroxaban17$24,540
TrulicityDulaglutide25$23,017
FarxigaDapagliflozin Propanediol28$19,269
Breo ElliptaFluticasone/Vilanterol39$17,580
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$12,585
NexletolBempedoic Acid22$8,508
SymbicortBudesonide/Formoterol Fumarate24$5,862
TradjentaLinagliptin11$5,430
MyrbetriqMirabegron11$4,763

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$27$114,362165 claims
Lilly USA, LLCMounjaro, Trulicity$19$65,80766 claims
Novo NordiskOzempic$14$37,53640 claims
GSKBreo Ellipta, Trelegy Ellipta$18$30,16555 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 3,610 family providers in Louisiana.

Other family in Hammond

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →